Archive - January 2023
Chemistree Solutions: Clinical Sales Specialist – Diabetes
January 20 2023 – Innovative trial design may have cost Lilly’s accelerated Alzheimer’s approval
NICE recommends Takeda’s Ninlaro triplet regimen
NICE recommends PTC Therapeutics’ Translarna reimbursement
FDA rejects accelerated approval for Eli Lilly’s Alzheimer’s drug, donanemab
Merck attempts to reduce levels of carcinogenic compounds in diabetes drugs
Intas Pharmaceuticals under FDA scrutiny after oversight in GMP documents
Alnylam and PTC Therapeutics’ rare disease drugs given backing by NICE